Investor Presentation August Nasdaq: ELGX
|
|
- Beverley Neal
- 5 years ago
- Views:
Transcription
1 Investor Presentation August 2010 Nasdaq: ELGX
2 Safe Harbor This Presentation Material has been prepared to assist interested parties in making their own evaluation of Endologix, Inc. (the Company ) and does not purport to be allinclusive or to contain all of the Information that a prospective Investor may require to make such an evaluation. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this Presentation Material. This Presentation Material contains forward-looking statements reflecting the Company s current assumptions and models regarding its business and operations in upcoming years. Interested parties are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitations, product development delays, changing regulations, the ability to attract and retain business partners, market acceptance of the Powerlink System, competition from other medical device companies and therapeutic applications, and the ability to provide the capital required for product development, operations and marketing. Neither the Company nor its affiliates, agents or representatives give any representation or warranty as to the accuracy or completeness of this Presentation Material. 2
3 Executive Summary Only Medical Device Company Focused Exclusively on $1+ Billion Aortic Stent Graft Market Innovative Product Portfolio with Exceptional Long- Term Clinical Results Strong Financial Performance 1H 2010 Revenue Growth of 21% 77% Gross Margins Significant Continued Growth Potential Expanding Sales Force Robust New Product Pipeline 3
4 Management Team John McDermott, President & CEO Bard Peripheral Vascular, IMPRA Bob Krist, CFO CardioNet, Datum, Bridge Medical, McGaw Inc Joe DeJohn, VP Sales Bard Peripheral Vascular, Bausch & Lomb Martin Tyler, VP Global Marketing Accumetrics, Bard USCI, Baxter Stefan Schreck Ph.D., VP Technology Edwards Lifesciences, Shiley, Asst. Prof. U.S.C. Janet Fauls, VP of Regulatory & Clinical Cardiogenesis, Edwards Lifesciences, Alliance Pharmaceutical Gary Sorsher, VP Quality Bard Peripheral Vascular, Cordis Todd Abraham, VP of Operations Edwards Lifesciences, Cordis 4
5 5 Endologix AAA Repair Minimally Invasive Endovascular Stent Graft
6 AAA Demographics / Prevalence Affects ~1.2 Million People in U.S. Age Related Disease (mostly men) 200,000 New Diagnoses Annually Approximately 65,000 AAA Procedures Annually 60% EVAR 40% Open Surgery 13 th Leading Cause of Death in the U.S. 6
7 Open AAA Surgery Extremely Invasive High Mortality and Morbidity Long Operating Times Long Hospital Recovery Numerous Complications 7
8 Compelling Clinical Benefits Drive EVAR Adoption New England Journal of Medicine Study* Highlights EVAR Advantages Endovascular Open Number of Patients 22,830 22,830 % Reduction Perioperative Mortality 1.2% 4.8% 75% Length of Hospital Stay 3.4 days 9.3 days 63% *NEJM 2008:
9 Infrarenal EVAR Market 35% 2010 = $880M 10% $90 $310M $570M 65% $790M 90% U.S. ROW PEVAR EVAR CAGR = 10% 9
10 Competitive Landscape Anatomical Fixation Proximal Fixation Powerlink - Endologix Talent Medtronic Excluder WL Gore Zenith Cook 10
11 U.S. Competitive Landscape Infrarenal Thoracic PEVAR Juxtarenal ELGX MDT COOK GORE In Development IDE Enrolling In Development Fixation Anatomical Proximal Proximal Proximal AAA Necks 18 32mm 18 32mm 18 32mm 19 29mm Profile (OD) 21F 22F 24F 21F 26F 20.4F 23F AAA Limbs 10 23mm 8 22mm 8 20mm mm Sales Force ~75 ~150 ~100 ~110 11
12 Clinical Results Combined Results of Three Prospective, Multicenter Clinical Trials (up to 5 yr follow-up) 157 Patients at 28 U.S. Centers 0% Aneurysm Ruptures 0% Conversion to Open Repair 0% Device Migration 0% Stent Fractures 0% Graft Fatigue 0% Aneurysm-Related Mortality Reduced or Stable Aneurysm Sacs in 95% of Patients at One Year J. ENDOVASC THER. 2010;17:
13 Capable of Treating a Wide Range of AAA Anatomies 13
14 Long Term Outcomes Month 1 Year 3 14 Courtesy of Rod White, M.D.
15 15 Stent Grafts
16 New AAA Delivery System Launched in 2009 Integrated Sheath and Hemostasis Valve Lower Procedure Times and Blood Loss Compared to Competition 16
17 Global Sales Force U.S. Direct Sales Force 58 Territories at the end of Q ~260 Years of EVAR Experience 30% Expansion Planned For 2010 Reps are Highly Trained Aortic Specialists Profile = Top Performing Cardiovascular Reps Extensive Training Program Provide Direct Physician Support in 95% of Procedures International Distributor Sales Force 13 Distributors Covering 22 Countries Includes Europe, Asia and South America 17
18 Historical Revenue Growth Annual CAGR = 66% $60 $50 $40 $ Millions $30 $20 $10 $
19 ELGX Growth Drivers U.S. Sales Force Expansion Increase International Presence Develop the Market for Percutaneous AAA New Product Pipeline Expanded Size Range (Q4 2010) AFX Endovascular System Fenestrated Device Thoracic Stent Graft 19
20 Product Launches US PMA Approval VISIFLEX Ectatic Limbs Powerlink XL IntuiTrak EnSnare Guidewires SurePass Technology Multiple New Product Launches over Past 24 Months Suprarenal Extensions IntuiTrak Express New Sizes PowerFit 20
21 EVAR Unmet Needs Ability to Treat Short Aortic Necks and Juxtarenal AAAs Fully Percutaneous Secondary Interventions Endoleaks Lifetime Surveillance 21
22 First ever Randomized Multi-Center Trial to Compare Percutaneous EVAR to Surgical Cut Down EVAR 20 sites Enrolling 210 Patients Collaboration with Abbott on Closure Devices Complete Enrollment 2011 Approval Anticipated in
23 PEVAR Study Sites Jon Matsumura, MD University of WI MC Madison, WI Paul Jones, MD Mercy Hospital Chicago, IL Daniel Clair, MD Cleveland Clinic Cleveland, OH Mark Fillinger, MD Dartmouth-Hitchcock MC Lebanon, NH John Harris, MD Stanford University MC Palo Alto, CA J. Michael Bacharach, MD Heart Hospital Sioux Falls, SD Vikram Rao, MD Lake Hospital Willoughby, OH Christian Bianchi, MD Loma Linda VA Loma Linda, CA Mark Morasch, MD Northwestern UMC Chicago, IL Homayoun Hashemi, MD Dipkanar Mukherjee, MD Inova Fairfax Falls Church, VA Nikhil Kansal, MD VA San Diego/UCSD San Diego, CA ProGlide Prostar XL Jim Melton, DO Oklahoma Heart Hosp Oklahoma City, OK Carlos Timaran, MD VA Dallas Health System Dallas, TX Frank Arko, MD UT Southwestern Dallas, TX Zvonimir Krajcer, MD Igor Gregoric, MD SLEH at TX Heart Institute Houston, TX J. Keith Thompson, DO Forrest MC Hattiesburg, MS JJ Karmacharya, MD Miami VA Miami, FL Alan Matsumoto, MD University of VA Charlottesville, VA Douglas MacMillan, MD Mission St. Joseph Asheville, NC Peter Nelson, MD, MS VA Gainesville/UFL Gainesville, FL
24 AFX Endovascular System Low Profile Delivery System Optimized for PEVAR New Strata Graft Material Complete size range to treat all AAA Anatomies 24
25 Fenestrated Stent Graft Device to Treat Short Necks and Juxtarenal Aneurysms Expands the EVAR Patient Population 15% of Diagnosed AAAs Provides a Better Solution for Patients Currently Treated Off-Label Adjustable Branches Accommodate a Variety of Renal Anatomies 25
26 Thoracic Stent Graft Flexible Stent Design Proprietary Graft Material Potential for in-vivo Fenestrations to Preserve LSA Low Profile 26
27 ELGX Market Opportunities $90M Aortic Stent TAA Graft $400M $500M Percutaneous Indication $790M Fenestrated Device $300M $500M $880M $1.7B AFX New Sizes 27 PEVAR Infrarenal Juxtarenal Thoracic
28 2010 Financial Guidance Global Revenue of $62M - $66M Increase over 2009 of 18% - 26% International Represents ~15% of Total Continue to Generate Positive Cash Flow from Operations 30% Increase in Sales Force 70% Increase in R&D 28
29 Balance Sheet ($000 s) 6/30/10 12/31/09 Cash $22,428 $24,065 Total Assets 52,708 51,292 Bank Debt Stockholders Equity 44,616 42,854 Total Liabilities & Equity $52,708 $51,292 29
30 Executive Summary ~$1.7 Billion Aortic Market Opportunity by 2015 Compelling Products in each Market Segment Innovative Product Portfolio with Exceptional Long-Term Clinical Results Sales Force Expansion and R&D Pipeline Funded by Operating Cash Flow Strong Financial Performance 2010 Sales Growth of 18% to 26% 77% Gross Margins 30
31 31 Nasdaq: ELGX
NASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationA New EVAR Device for Infrarenal AAAs
A New EVAR Device for Infrarenal AAAs Peter Nelson, MD, MS Assistant Professor of Surgery MM0203 Rev. 01 Current U.S. EVAR Devices Anatomical Fixation Proximal Fixation Powerlink - Endologix Excluder WL
More informationLOWERING THE PROFILE RAISING THE BAR
LOWERING THE PROFILE RAISING THE BAR INNOVATIVE LOW PROFILE. ADVANCED CLINICAL PERFORMANCE. The AFX TM Endovascular AAA System integrates anatomical fixation with an advanced delivery system and graft
More informationHistory of the Powerlink System Design and Clinical Results. Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ
History of the Powerlink System Design and Clinical Results Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ Powerlink System: Unibody-Bifurcated Design Long Main Body Low-Porosity Proprietary eptfe
More informationOvation. Sean Lyden, MD Department Chair, Vascular Surgery Cleveland Clinic
Ovation Sean Lyden, MD Department Chair, Vascular Surgery Cleveland Clinic Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationCAUTION: The Nellix EndoVascular Aneurysm Sealing System is an investigational device. Limited by federal (or United States) law to investigational
Safety and Effectiveness Results of the Nellix System IDE Pivotal Trial for Endovascular Aneurysm Sealing PRESENTED BY: Jeffrey P. Carpenter, MD National Principal Investigator Professor and Chairman,
More information14F OD Ovation Abdominal Stent Graft System
14F OD Ovation Abdominal Stent Graft System 2 Year Results from the European Study Dierk Scheinert, MD Center for Vascular Medicine Angiology and Vascular Surgery Park Hospital Leipzig, Germany Disclosure
More informationView Report Details. Global Aortic Aneurysm Market: Trends and Opportunities ( )
View Report Details Global Aortic Aneurysm Market: Trends and Opportunities (2014-2019) View Report Details Scope of the Report The report titled Global Aortic Aneurysm Market: Trends and Opportunities
More informationNellix Endovascular System: Clinical Outcomes and Device Overview
Nellix Endovascular System: Clinical Outcomes and Device Overview Jeffrey P. Carpenter, MD Professor and Chief, Department of Surgery CAUTION: Investigational device. This product is under clinical investigation
More informationMy personal experience with INCRAFT in standard and challenging cases
My personal experience with INCRAFT in standard and challenging cases G Pratesi, MD Vascular Surgery University of Rome Tor Vergata giovanni.pratesi@uniroma2.it Disclosure Speaker name: Giovanni Pratesi,
More informationCurrent Status of EVAR for Infrarenal AAA. 31 st Annual Florida Vascular Society. PENN Surgery
Current Status of EVAR for Infrarenal AAA 31 st Annual Florida Vascular Society PENN Surgery No Disclosures Stent Grafts Design Related Differences What really matters? Modular Unibody Supported Unsupported
More informationThe Ventana Off-the-Shelf Graft for Pararenal AAA. Andrew Holden Associate Professor of Radiology Auckland Hospital
The Ventana Off-the-Shelf Graft for Pararenal AAA Andrew Holden Associate Professor of Radiology Auckland Hospital Disclosures Andrew Holden, MBChB, FRANZCR Investigator in Nellix and Ventana Trials Clinical
More informationToward Total Endovascular Therapy of the Aorta. Adam W. Beck, MD. Associate Professor of Surgery Division of Vascular Surgery and Endovascular Therapy
Toward Total Endovascular Therapy of the Aorta Adam W. Beck, MD Associate Professor of Surgery Division of Vascular Surgery and Endovascular Therapy University of Alabama at Birmingham Disclosures Grant
More informationOptimizing Accuracy of Aortic Stent Grafts in Short Necks
Optimizing Accuracy of Aortic Stent Grafts in Short Necks Venkatesh Ramaiah, MD, FACS Medical Director Arizona Heart Hospital Director Peripheral Vascular and Endovascular Research Arizona Heart Institute
More informationLess Invasive EVAR Transitioning to a Fast-Track Protocol
Less Invasive EVAR Transitioning to a Fast-Track Protocol Mario Lachat, MD University of Zurich Department of Cardiovascular Surgery Switzerland LINC 2015 1 Disclosure Speaker name: Mario Lachat, MD I
More informationCurrent Status of Abdominal Aortic Stent Grafts. John R. Laird Professor of Medicine Director of the Vascular Center UC Davis Medical Center
Current Status of Abdominal Aortic Stent Grafts John R. Laird Professor of Medicine Director of the Vascular Center UC Davis Medical Center Autumn Greetings Disclosure Statement of Financial Interest Within
More informationAbdominal and thoracic aneurysm repair
Abdominal and thoracic aneurysm repair William A. Gray MD Director, Endovascular Intervention Cardiovascular Research Foundation Columbia University Medical Center Abdominal Aortic Aneurysm Endografts
More informationDegeneration of the Neck Post Implementation - a New Era of AAA Stent
Degeneration of the Neck Post Implementation - a New Era of AAA Stent New Mexico Heart Institute Albuquerque, New Mexico USA - Gore Current FDA-Approved EVAR Devices Sealing Mechanism Endologix Lombard
More informationChallenging anatomies demand versatility.
Challenging anatomies demand versatility. The Distinct Advantages of Separating Seal and Fixation ANATOMICAL FIXATION Unlike proximal fixation designs, the AFX bifurcated unibody endograft allows for natural
More informationINCRAFT system: Update from the Pivotal INSPIRATION Study
INCRAFT system: Update from the Pivotal INSPIRATION Study Michel S. Makaroun MD Co-Director, UPMC Heart and Vascular Institute Professor and Chair, Division of Vascular Surgery University of Pittsburgh
More informationAccess More Patients. Customize Each Seal.
Access More. Customize Each Seal. The Least Invasive Path Towards Proven Patency ULTRA LOW PROFILE TO EASE ADVANCEMENT The flexible, ultra-low 12F ID Ovation ix delivery system enables you to navigate
More information2015 Clinical Update Endovascular Systems for AAA Repair
Endovascular Systems for AAA Repair 2 Musick Irvine, CA 92618 Tel 949.595.7200 Fax 949.612.1893 www.endologix.com TABLE OF CONTENTS Section Page ABSTRACT... 3 READER S GUIDE... 4 SECTION 1: US PIVOTAL
More informationConsiderations for a Durable Repair
Considerations for a Durable Repair Eric Verhoeven, MD, PhD, A. Katsargyris, MD Department of Vascular and Endovascular Surgery, Paracelsus Medical University, Nuremberg, Germany Disclosures William Cook
More informationEndovascular Repair o Abdominal. Aortic Aneurysms. Cesar E. Mendoza, M.D. Jackson Memorial Hospital Miami, Florida
Endovascular Repair o Abdominal Aortic Aneurysms Cesar E. Mendoza, M.D. Jackson Memorial Hospital Miami, Florida Disclosure Nothing to disclose. 2 Mr. X AAA Mr. X. Is a 70 year old male who presented to
More informationThe Auckland Experience with the Nellix EVAS System. Andrew Holden, MBChB, FRANZCR
The Auckland Experience with the Nellix EVAS System Andrew Holden, MBChB, FRANZCR Disclosure Speaker name: Associate Professor Andrew Holden I have the following potential conflicts of interest to report:
More informationTalent Abdominal Stent Graft
Talent Abdominal with THE Xcelerant Hydro Delivery System Expanding the Indications for EVAR Treat More Patients Short Necks The Talent Abdominal is the only FDA-approved device for proximal aortic neck
More informationAortic Neck Issues Associated Clinical Sequelae/Implications for Graft Choice
Aortic Neck Issues Associated Clinical Sequelae/Implications for Graft Choice Eric Verhoeven, MD, PhD, A. Katsargyris, MD Department of Vascular and Endovascular Surgery, Paracelsus Medical University,
More informationAnalysis of Type IIIb Endoleaks Encountered with Endologix Endografts
Analysis of Type IIIb Endoleaks Encountered with Endologix Endografts Alan R. Wladis, MD, FACS, David Varnagy, MD, FACS, Manuel R. Perez-Izquierdo, MD, Mark Ranson, MD FACS, Delos Clift, MD FACS, Rebecca
More informationCURRICULUM VITAE. Jim G. Melton, D.O. Oklahoma Heart Hospital Physicians 4050 W. Memorial Rd., Third Floor Oklahoma City, Oklahoma 73120
CURRICULUM VITAE Oklahoma Heart Hospital Physicians 4050 W. Memorial Rd., Third Floor (405)608-3800 Phone (405)608-3838 Fax BUSINESS ADDRESS: Oklahoma Heart Hospital Physicians (OHHP) 4050 W. Memorial
More informationState of the Art of PEVAR
State of the Art of PEVAR Zvonimir Krajcer, MD Program Director- Peripheral Vascular Interventions Department of Cardiology, St. Luke s Episcopal Hospital and Texas Heart Institute, Houston, TX Disclosures
More informationHostile Proximal Neck: A New Conformable EVAR Device
Hostile Proximal Neck: A New Conformable EVAR Device Young-Guk Ko, M.D., Seoul, Korea Currently Available Devices for EVAR in Korea, 2018 Zenith Flex, Cook Endurant IIs, Medtronic INCRAFT, Cordis AFX2,
More informationBilateral use of the Gore IBE device for bilateral CIA aneurysms and a first interim analysis of the prospective Iceberg registry
Bilateral use of the Gore IBE device for bilateral CIA aneurysms and a first interim analysis of the prospective Iceberg registry Michel MPJ Reijnen, MD, PhD Department of Vascular Surgery, Rijnstate Hospital
More informationReduction in cardiovascular related adverse events following active sac management with Nellix vs. EVAR: Are there biological advantages?
February 1, 2018 Reduction in cardiovascular related adverse events following active sac management with Nellix vs. EVAR: Are there biological advantages? Patrick Berg M.D. Marienhospital Kevelaer Germany
More informationLessons learned from Ch-EVAR for the treatment of. Miltos Matsagkas MD, PhD, FEBVS Professor of Vascular Surgery University of Thessaly
Lessons learned from Ch-EVAR for the treatment of pararenal AAAs Miltos Matsagkas MD, PhD, FEBVS Professor of Vascular Surgery University of Thessaly Ch-EVAR Ch-EVAR = Chimney-EVAR Placement of single
More informationImproving Endograft Durability with EndoAnchors
Improving Endograft Durability with EndoAnchors William D. Jordan, Jr., M.D. John E. Skandalakis Chair in Surgery Professor and Chief Division of Vascular Surgery and Endovascular Therapy Emory University
More informationMid-term results from ANCHOR: How does this data influence the treatment algorithm for hostile EVAR anatomies
Mid-term results from ANCHOR: How does this data influence the treatment algorithm for hostile EVAR anatomies Jean-Paul P.M. de Vries Head Department of Surgery, University Medical Centre Groningen The
More informationAnatomy-Driven Endograft Selection for Abdominal Aortic Aneurysm Repair S. Jay Mathews, MD, MS, FACC
Anatomy-Driven Endograft Selection for Abdominal Aortic Aneurysm Repair S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton, FL, USA Disclosures
More informationEndovascular Treatment of the Aorta with Fenestrated and Branched Grafts
Endovascular Treatment of the Aorta with Fenestrated and Branched Grafts Eric LG Verhoeven,MD, PhD, A. Katsargyris, MD Vascular and Endovascular Surgery, Paracelsus Medical University, Nuremberg, Germany
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationDurable outcomes. Proven performance.
Durable outcomes. Proven performance. GORE EXCLUDER AAA Endoprosthesis GORE EXCLUDER Iliac Branch Endoprosthesis GORE EXCLUDER AAA Endoprosthesis The most-studied* EVAR stent graft designed for durable
More informationOff-the-Shelf Devices. Mark A Farber, MD FACS Director, Aortic Center Professor of Radiology and Surgery University of North Carolina
Off-the-Shelf Devices Mark A Farber, MD FACS Director, Aortic Center Professor of Radiology and Surgery University of North Carolina Disclosures Cook - Research Support, Consultant, Clinical Trials WL
More informationChimney endovascular aneurysm sealing (ch-evas) for ruptured abdominal aortic aneurysms (AAA) due to type Ia endoleak following failed EVAS
Chimney endovascular aneurysm sealing (ch-evas) for ruptured abdominal aortic aneurysms (AAA) due to type Ia endoleak following failed EVAS Saritphat Orrapin MD FRCS (Thailand), Thoetphum Benyakorn, Tunyarat
More informationENCORE, a Study to Investigate the Durability of Polymer EVAR with Ovation A Contemporary Review of 1296 Patients
ENCORE, a Study to Investigate the Durability of Polymer EVAR with Ovation A Contemporary Review of 1296 Patients The Ovation System is approved to treat infrarenal abdominal aortic aneurysms and is not
More informationEVAR replaced standard repair in most cases. Why?
EVAR replaced standard repair in most cases. Why? Initial major steps in endograft evolution Papazoglou O. Konstantinos M.D. The story of a major breakthrough in vascular surgery 1991 Parodi introduces
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationPredictors of abdominal aortic aneurysm sac enlargement after EVAR Longterm results from the ENGAGE Registry
Predictors of abdominal aortic aneurysm sac enlargement after EVAR Longterm results from the ENGAGE Registry D. Böckler Department of Vascular and Endovascular Surgery University Hospital Heidelberg Disclosure
More informationTreatment options of late failures of EVAS. Michel Reijnen Rijnstate Arnhem The Netherlands
Treatment options of late failures of EVAS Michel Reijnen Rijnstate Arnhem The Netherlands Disclosure Speaker name: Michel Reijnen I have the following potential conflicts of interest to report: Consulting
More informationREFERENCE CODE GDME1117CFR PUBLICAT ION DATE OCTOBER 2014 AORTIC STENT GRAFTS EU ANALYSIS AND MARKET FORECASTS
REFERENCE CODE GDME1117CFR PUBLICAT ION DATE OCTOBER 2014 AORTIC STENT GRAFTS Executive Summary Table below provides the key metrics for aortic stent grafts in the 5EU (France, Germany, Italy, Spain, and
More informationDurability of The Endurant Stent-Graft through 5 Years
Durability of The Endurant Stent-Graft through 5 Years Michel S. Makaroun MD Co-Director, UPMC Heart and Vascular Institute Professor and Chair, Division of Vascular Surgery University of Pittsburgh School
More informationHostile Neck During EVAR, The Role Of Endoanchores
Hostile Neck During EVAR, The Role Of Endoanchores Samer Koussayer, MD, FACS, RVT Prof, Al Faisal University Section Head and consultant Vascular & Endovascular Surgery Division King Faisal Specialist
More informationEarly Clinical Results with the Valiant Mona LSA Branch Stent-Graft
Early Clinical Results with the Valiant Mona LSA Branch Stent-Graft Frank R. Arko III, MD Professor of Cardiovascular Surgery Director, Endovascular Surgery Co-Director, Aortic Institute Carolinas Medical
More informationLow profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster
Low profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster Disclosure Speaker name:...michel Bosiers... I have the following potential conflicts of interest to report: Consulting Employment
More informationOvation 4-Year Results Pivotal Study to Evaluate the Safety and Effectiveness of the Ovation System
Ovation 4-Year Results Pivotal Study to Evaluate the Safety and Effectiveness of the Ovation System Vascular Health Partners Glens Falls, New York Disclosure Speaker name: I have the following potential
More informationPatient selection in Hostile Necks and how. to prevent endoleaks a word of caution
Patient selection in Hostile Necks and how to prevent endoleaks a word of caution P M Kasprzak, K. Pfister Department of Vascular Surgery Endovascular Surgery University Hospital Regensburg, Germany Conflict
More informationTriVascular Ovation Prime Abdominal Stent Graft System
TriVascular Ovation Prime Abdominal Stent Graft System Science of the Seal O-Ring Sealing Technology O-Ring Sealing in Proven Engineering Solutions O-rings are designed to seal by blocking the flow of
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationYoung-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
Young-Guk Ko, M.D., Dangas G, J Am Coll Cardiol Intv 2012;5:1071 All-cause Mortality Dangas Severance G, J Am Coll Cardiovascular Cardiol Intv Hospital, 2012;5:1071 Yonsei University Health System Aneurysm-related
More informationIncreased Flexibility of AneuRx Stent-Graft Reduces Need for Secondary Intervention Following Endovascular Aneurysm Repair
583 Increased Flexibility of AneuRx Stent-Graft Reduces Need for Secondary Intervention Following Endovascular Aneurysm Repair Frank R. Arko, MD; W. Anthony Lee, MD; Bradley B. Hill, MD; Paul Cipriano,
More informationGlobal Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast ( )
Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast (2017-2022) By Region- North America, Europe, APAC and RoW By Country
More informationChallenges with Complex Anatomies Advancing Care in Endovascular Aortic Treatment
Challenges with Complex Anatomies Advancing Care in Endovascular Aortic Treatment Robert Y. Rhee, MD Chief, Vascular and Endovascular Surgery Director, Aortic Center Maimonides Medical Center Brooklyn,
More informationEvolution of gender-related differences in outcome of EVAR
Evolution of gender-related differences in outcome of EVAR Erik Debing Department of Vascular Surgery University Hospital Brussels Disclosure Speaker name: ERIK DEBING... I have the following potential
More informationChungbuk Regional Cardiovascular Center, Division of Cardiology, Departments of Internal Medicine, Chungbuk National University Hospital Sangmin Kim
Endovascular Procedures for Isolated Common Iliac and Internal Iliac Aneurysm Chungbuk Regional Cardiovascular Center, Division of Cardiology, Departments of Internal Medicine, Chungbuk National University
More informationConflicts of Interest. When and Why Complex EVAR in Tx of juxta/suprarenal AAA? Summary. Infrarenal EVAR for short necks 2y postop
When and Why Complex EVAR in Tx of juxta/suprarenal AAA? Tim Resch MD Vascular Center Skane University Hospital Conflicts of Interest COOK Medical - Consulting, Speakers Bureau, IP, Research support Medtronic
More informationRedo treatment and open conversion after TEVAR
Redo treatment and open conversion after TEVAR Roberto Chiesa Vascular Surgery, Vita-Salute University Scientific Institute San Raffaele Milan, Italy Number of procedures Off-Label indications for TEVAR
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationMODERN METHODS FOR TREATING ABDOMINAL ANEURYSMS AND THORACIC AORTIC DISEASE
MODERN METHODS FOR TREATING ABDOMINAL ANEURYSMS AND THORACIC AORTIC DISEASE AAA FACTS 200,000 New Cases Each Year Ruptured AAA = 15,000 Deaths per Year in U.S. 13th Leading Cause of Death 80% Chance of
More informationAorfix Pythagoras US Clinical Trial:
Overall 1 Year Results from the Aorfix Pythagoras US Clinical Trial: 1 st IDE Study in Highly Angulated 60 133 Aortic Necks Mark Fillinger MD for the PYTHAGORAS Investigators Disclosure Speaker name: Mark
More informationTechnique and Tips for Complicated AAA Cases with Stent Graft
Technique and Tips for Complicated AAA Cases with Stent Graft Seung-Woon Rha, MD, PhD FACC, FAHA, FESC, FSCAI, FAPSIC Cardiovascular Center, Korea University Guro Hospital Mar 15, 2018 LINC AP 2018 Endoleak;
More informationExceptions to the Rules: Abdominal and Thoracic Aneurysms
Exceptions to the Rules: Abdominal and Thoracic Aneurysms Jason Bayne MD, FRCSC Vascular Surgery Jewish General Hospital Assistant Professor, Program Director McGill University Objectives Risk factors
More informationSanti Trimarchi, MD, PhD Vascular Surgeon Thoracic Aortic Research Center, Director IRCCS Policlinico San Donato University of Milan
The Gore GREAT Registry: Update about a real life data collection Santi Trimarchi, MD, PhD Vascular Surgeon Thoracic Aortic Research Center, Director IRCCS Policlinico San Donato University of Milan Disclosures
More informationEight Year Experience with Type I Endoleaks at a Tertiary Care Center
Eight Year Experience with Type I Endoleaks at a Tertiary Care Center Adam Tanious MD, Megan Carroll MD, Mathew Wooster MD, Andrew Jung BA, Marcello Giarelli MSN, Martin Back MD, Bruce Zwiebel MD, Peter
More informationFEVAR FIFTEEN YEARS OF EFFICIENCY E.DUCASSE MD PHD FEBVS CHU DE BORDEAUX
FEVAR FIFTEEN YEARS OF EFFICIENCY E.DUCASSE MD PHD FEBVS CHU DE BORDEAUX 2018 A BIT OF HISTORY First use of F-EVAR : 1990s Park et al. J Vasc Interv Radiol. 1996;7:819-823. Faruqi et al. J Endovasc Surg.
More informationHow to select FEVAR versus EVAR + endoanchors in short-necked AAAs
How to select FEVAR versus EVAR + endoanchors in short-necked AAAs Jean-Paul P.M. de Vries, Richte C.L. Schuurmann St. Antonius Hospital Nieuwegein, The Netherlands 21st Critical Issues Congress Nuernberg,
More informationEVAR Revision Setting - How can Heli-FX EndoAnchors improve the outcomes?
D. Böckler Department of Vascular and Endovascular Surgery University Hospital Heidelberg EVAR Revision Setting - How can Heli-FX EndoAnchors improve the outcomes? Disclosures Speaker name: Dittmar Böckler
More informationNo Neck Is Needed! Treat the Aneurysm Instead! Andrew Holden, MD Associate Professor of Radiology Auckland City Hospital
No Neck Is Needed! Treat the Aneurysm Instead! Andrew Holden, MD Associate Professor of Radiology Auckland City Hospital Disclosures Andrew Holden, MBChB, FRANZCR No financial investment to disclose Investigator
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA167; Endovascular stent-grafts for abdominal aortic aneurysms Final recommendation post consultation The guidance should
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationWhat does the data tell us about outcomes of EVAR in challenging anatomy?
What does the data tell us about outcomes of EVAR in challenging anatomy? UCSF Vascular Surgery Symposium 2018 Sukgu M Han, MD, MS Assistant Professor of Clinical Surgery Co-director, Comprehensive Aortic
More informationTreating very short necks ( 4mm <10mm) using the Endurant stent graft + EndoAnchors: 1-year results and current insights
Treating very short necks ( 4mm
More informationSolutions For The Aging Spine
Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our
More informationGORE EXCLUDER AAA Endoprosthesis demonstrates long-term durability. Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands
GORE EXCLUDER AAA Endoprosthesis demonstrates long-term durability Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands Disclosure Speaker name: Michel Reijnen I have the following potential conflicts
More informationPerformance of the conformable GORE TAG device in Type B aortic dissection from the GORE GREAT real world registry
University of Milan Thoracic Aortic Research Center Performance of the conformable GORE TAG device in Type B aortic dissection from the GORE GREAT real world registry Santi Trimarchi, MD, PhD Associate
More informationEVAS using Nellix in my practice Where are we today?
EVAS using Nellix in my practice Where are we today? Prof. dr. Michel MPJ Reijnen Department of Vascular Surgery, Rijnstate Hospital Arnhem Faculty of Science and Technology, University of Twente The Netherlands
More informationEXPERIENCE AFTER 500 ENDOLUMINAL STENT GRAFTS. DEVICES SPECIFIC OUTCOME AND LESSONS LEARNED.
EXPERIENCE AFTER 500 ENDOLUMINAL STENT GRAFTS. DEVICES SPECIFIC OUTCOME AND LESSONS LEARNED. A/Prof. B. Patrice Mwipatayi MD, MMed (Surg), MClinEd (Melb), FCS, FRACS Department of Vascular Surgery, Royal
More informationTranscatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
More informationTHE ENDURANT STENT GRAFT IN HOSTILE ANEURYSM NECK ANATOMY
THE ENDURANT STENT GRAFT IN HOSTILE ANEURYSM NECK ANATOMY Patrice Mwipatayi FCS (SA), MMed, FRACS Professor of Vascular surgery Royal Perth Hospital, University of Western Australia, Perth, WA Co-Authors:
More informationStandardization of the CHEVAR procedure: How a standard approach has improved outcomes. Prof Peter Holt St George s, London
Standardization of the CHEVAR procedure: How a standard approach has improved outcomes Prof Peter Holt St George s, London Disclosure Speaker name: Prof Peter Holt I have the following potential conflicts
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationThree year experience with multilayer stent in the treatment of thoracoabdominal aneurysms no evidence for aneurysm stabilization
Three year experience with multilayer stent in the treatment of thoracoabdominal aneurysms no evidence for aneurysm stabilization Thomas Larzon, MD, PhD Head of Vascular Surgery Dept of Cardiothoracic
More informationRadRx Your Prescription for Accurate Coding & Reimbursement Copyright All Rights Reserved.
Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck, RHIA, CCS-P, RCC, CIRCC, AAPC Fellow President & Senior Consultant INDICATION: Abdominal aortic aneurysm. INTERVENTIONAL RADIOLOGIST:
More informationType 1a Endoleak in hostile neck anatomies: Endoanchor can fix it! D. Böckler University Hospital Heidelberg, Germany
Type 1a Endoleak in hostile neck anatomies: Endoanchor can fix it! D. Böckler University Hospital Heidelberg, Germany Disclosures Speaker name: Dittmar Böckler I have the following potential conflicts
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationZenith Renu AAA Converter Graft. Device Description Planning and Sizing Deployment Sequence Patient Follow-Up
Zenith Renu AAA Converter Graft Device Description Planning and Sizing Deployment Sequence Patient Follow-Up Device description: Device indications The Zenith Renu AAA Converter Graft with Z-Trak Introduction
More informationFaculty Disclosure. Glue, Particulates, Thrombin, Coils and the Kitchen Sink for Type II Endoleak Management. Background.
Glue, Particulates, Thrombin, Coils and the Kitchen Sink for Type II Endoleak Management Faculty Disclosure I disclose the following financial relationships: UCSF Vascular Symposium 2013 Receive grant/research
More informationAAA: DEBATE THERE ARE NO LIMITS USING EVAR FOR AAA. 2 nd -3 rd June 2016.
AAA: DEBATE THERE ARE NO LIMITS USING EVAR FOR AAA JORGE FERNÁNDEZ NOYA ANGIOLOGY AND VASCULAR SURGERY DEPARTMENT UNIVERSITARY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA 2 nd -3 rd June 2016. 1888 ENDOANEURYSMORRHAPHY
More information